Business Wire

Sphera Signs Agreement to Acquire riskmethods, a Leader in Artificial Intelligence Supply Chain Risk Management Software

13.9.2022 16:30:00 EEST | Business Wire | Press release

Share

Sphera, a leading global provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services, announces it has entered into an agreement to acquire riskmethods, a Munich, Germany-based, award-winning software company specializing in supply chain risk management (SCRM).

Founded in 2013, riskmethods’ software as a service (SaaS) solution harnesses cutting-edge artificial intelligence (AI), big data and machine learning to protect its customers’ supply chain networks. Its software platform collects supplier data and real-time information, distinguishes critical signals from “noise” and provides users with detailed status of suppliers, so they can prevent business disruption risk before it materializes and achieve supply chain transparency.

“riskmethods’ cloud-based software identifies, analyzes and helps mitigate all types of supply chain risk, including monitoring sustainability practices and ESG compliance in the supply chain. Their innovative approach to SCRM bolsters Sphera’s capabilities in offering a Scope 3 emissions monitoring and reporting solution and furthers our mission of creating a safer, more sustainable and productive world,” said Paul Marushka, Sphera’s president and CEO. “And their presence in Europe and the U.S. reinforces our ability to serve our expanding global customer base.”

The company’s SCRM software solution is a robust tool for managing risk in increasingly complex supply chains, as well as handling ever-expanding regulatory compliance. With global companies operating in a world of disruption and turbulence—pandemics and climate change, to name a few—riskmethods offers real-time SCRM solutions that enable businesses to proactively manage potential supply chain risks and comply with emerging operational and ESG regulations.

“For the last 10 years, riskmethods has been empowering businesses to master supply chain risk and create reliable supply networks,” said Heiko Schwarz, riskmethods’ CEO and founder. “Adding our advanced AI and machine-learning SCRM software solution to Sphera’s product portfolio will enable us to further our reach across the globe and help even more customers manage supply chain risk. We are excited to join the Sphera family of leading ESG software, data and consulting solutions.”

Kelly Wannop, Managing Director at Blackstone, said, “Blackstone’s 2021 investment in Sphera reflected our conviction in Sphera’s ESG mission and growth. The planned acquisition of riskmethods further demonstrates our commitment to helping Sphera expand their operational ESG solutions.” Eli Nagler, a Senior Managing Director at Blackstone, continued, “We are excited to welcome riskmethods to Sphera and eager to extend their SCRM solutions to even more customers.”

ReedSmith LLP and Simpson Thatcher & Bartlett LLP served as legal advisors to Sphera and Blackstone while Evercore served as the financial advisor. For the sellers, DLA Piper served as legal advisor, and Stifel served as the financial advisor.

About Sphera

Sphera is the leading provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services focusing on Environment, Health, Safety & Sustainability (EHS&S), Operational Risk Management and Product Stewardship. For more than 30 years, we have served over 6,700 customers and a million-plus users in 80 countries to help companies keep their people safe, their products sustainable and their operations productive. Learn more about Sphera at www.sphera.com. Follow Sphera on LinkedIn.

About riskmethods

riskmethods enables organizations worldwide to identify, analyze and mitigate all types of supply chain risk management (SCRM). riskmethods’ software utilizes artificial intelligence (AI) and machine learning to protect its customers’ supply chain network. Its software platform collects supplier data and real-time information, distinguishes critical signals from “noise” and provides users with visibility across multiple tiers of their supply chain, so they can mitigate business disruption risk and achieve supply chain transparency. The company’s 200+ employees across 4 offices worldwide serve more than 225 enterprise customers. More information can be found at www.riskmethods.net.

About Blackstone

Blackstone is the world’s largest alternative investment firm. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $941 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, infrastructure, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Astrid Dickinson
Aspectus Group
sphera@aspectusgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release

The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye